ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
4FRONT-1, the first 4D-150 wet AMD phase 3 trial, is being conducted in North America in treatment-naïve patients with an ...
-- More than half of patients free of injection at median follow-up of 1.7 years at 2 x 10^11 vg/eye -- “We have now followed all wet AMD patients in the OPTIC trial for a minimum of a year, and in ...
A real-world analysis showed increased rates of undertreatment and attrition with anti-VEGF injections in patients with wet ...
4DMT Molecular Therapeutics Inc. is looking ahead to phase III as positive data continue to roll out for gene therapy candidate 4D-150 in wet age-related macular degeneration (AMD), with the results ...
Anti–vascular endothelial growth factor (VEGF) medications have been a mainstay of treatment for wet age-related macular degeneration (wet AMD) for 20 years — and for good reason. The medication has ...
Patients with neovascular age‑related macular degeneration (AMD) whose retinal fluid cleared within 12 weeks of starting faricimab were more likely to have longer intervals between injections later in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results